Mallinckrodt Pays $117M for This Bay Area Biotech and Its Failed Liver Drug Post author:Sam Post published:November 1, 2017 Post category:BioPharma Mallinckrodt has agreed to buy Ocera Therapeutics in a deal that could hit $117M. Source: BioSpace You Might Also Like Celgene Partners with Prothena Therapeutics in Potential $2B Deal March 20, 2018 Most Common Mistake Scientists Make When Applying for a Job July 19, 2017 Anavex Issued New U.S. Patent For Composition Of Matter Covering ANAVEX 2-73 September 4, 2017
